-

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

Jerry Hu, M.D. appointed to Board of Directors

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its fully subscribed Series B-2 financing of $3 million.

This investment will support iVeena’s pursuit of advancing their innovative pediatric myopia program. All IND-enabling studies are well underway supporting a targeted IND submission in H1-2025.

“We are pleased to welcome Dr. Jerry Hu to our Board as an independent director,” said President and Founder, Bala Ambati, M.D., Ph.D., MBA. “Dr. Hu is a world-renowned ophthalmologist who stands at the forefront of cutting-edge ophthalmic innovations bringing significant value to our long-term strategy.”

About IVMED-85

IVMED-85 is a daily eye drop that strengthens scleral and corneal collagen crosslinks through LOX activation, potentially leading to improved refraction and a decrease in the rate of axial elongation. IVMED-85 is expected to begin a Phase 2 clinical study in progressive myopia in 2025.

About iVeena

iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive diseases. iVeena has licensed its lead asset to Glaukos Corporation, IVMED-80, an Orphan Drug Designated eye drop for keratoconus. iVeena is developing IVMED-85, a first in class, investigational eyedrop formulation for pediatric myopia.

Contacts

Corporate Contact:
Michael Burr, MS, MBA
Vice President of Product Development
mburr@iveenamed.com

Industry:

iVeena Delivery Systems, Inc.

Details
Headquarters: Salt Lake City, Utah
CEO: Robert Dempsey
Employees: 8
Organization: PRI
Release Versions
English

Contacts

Corporate Contact:
Michael Burr, MS, MBA
Vice President of Product Development
mburr@iveenamed.com

Social Media Profiles
iVeena LinkedIn
More News From iVeena Delivery Systems, Inc.

iVeena Awarded $2 Million National Eye Institute Grant to Advance Novel Therapy for Pediatric Myopia

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company, today announced it has been awarded a $2 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH). The funding will advance the development of novel topical eye drops being investigated to control pediatric myopia and other refractive disorders. iVeena’s research is led by Sarah Molokhia, PhD, V...

iVeena Announces IND Submission to the U.S. FDA for a Phase 2 Clinical Trial for Pediatric Myopia

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IVMED-85 for the treatment of pediatric myopia. “Today’s announcement is an important milestone for iVeena in our journey to offer patients a novel therapeutic option,” said President and Founder, Bala Ambati...

iVeena Awarded NEI-SBIR Grant For Progressive Myopia Drug Candidate IVMED-85

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research (SBIR) grant of $345,000 for iVeena’s progres...
Back to Newsroom